drugset / Trial / NCT01155999

Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children.

NCT01155999

Phase 3 Completed 286 enrolled Laboratoires Thea
RandomizedParallel-groupSingle-blindTreatment

Summary

Efficacy/Safety of T1225, in comparison to reference product, for the treatment of purulent bacterial conjunctivitis of children.

Timeline

Start
2008-12
Primary completion
2011-02
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject T1225 Unknown Topical
Comparator Tobramycin Small molecule 0.3 % Topical